Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Throughout her career, One2Treat’s Émilie Barré has focused on developing both the analytical and leadership aspects ...

Manas AI secures funding led by General Catalyst to scale AI-driven drug discovery, tackling cancer and rare diseases.